Deutetrabenazine

Limits on what this shows

• Key negative/null finding: No significant cell-viability loss with tetrabenazine, versus significant losses with both mitochondrial-toxin comparators in the same experiment - the central finding of this entry.
• At-risk subgroups: None identified; no human or subgroup data exists for this category and this drug.
• Counter-evidence on record: No study was located showing tetrabenazine or deutetrabenazine directly damages mitochondrial structure, membrane integrity, or biogenesis. The only tetrabenazine-specific mitochondrial data located is this negative/reassuring in vitro result; it is reported here as the finding itself, not as a null result being explained away.

Regulatory status

Not addressed in the Austedo/Austedo XR label; no mitochondrial-toxicity warning or monitoring requirement.

Population evidence

In vitro only. MN9D mouse dopaminergic neuronal cell line; tetrabenazine 1 micromolar for 1 hour tested alongside rotenone (1.5 micromolar) and antimycin A (10 micromolar), the classic mitochondrial Complex I and Complex III inhibitors. Rotenone and antimycin A significantly reduced cell viability; tetrabenazine had no significant effect on cell viability in the same assay (Adetuyi & Wimalasena, Toxics, 2025). This is tetrabenazine-specific (cohort test passed for the parent compound) but not deutetrabenazine-specific and not human, so it is capped at yellow under the class-extrapolation rule.

Mechanism

VMAT2 inhibition reduces vesicular packaging of monoamines without directly engaging electron-transport-chain complexes. The study authors concluded that "mitochondrial dysfunction...is independent of...vesicular monoamine transporter-2 inhibition."

Counter-evidence held on record

This rests on a single in vitro cell-line study of the parent compound tetrabenazine, not of deutetrabenazine, and not of a human subject. It should be read as the best currently available mechanistic evidence on this category - which happens to run against a mitochondrial-burden mechanism - not as a clearance of mitochondrial safety. No supplementation is suggested by this entry.

Limits on what this shows

• Key negative/null finding: No significant reactive-oxygen-species elevation and no significant cell-viability loss with tetrabenazine in the MN9D assay - directly contradicting the oxidative-stress hypothesis that the C. elegans antioxidant-rescue result is consistent with.
• At-risk subgroups: None identified in humans; theoretical only, and contested even at the mechanistic level.
• Counter-evidence on record: The two same-class sources directly disagree on whether a measurable oxidative-stress response occurs; this contest is disclosed rather than resolved, since no human or deutetrabenazine-specific oxidative-stress marker study exists either way. Separately, a body of research exists on antioxidants (vitamin E, coenzyme Q10) as adjunct treatment for the disease-intrinsic oxidative pathology of tardive dyskinesia and Huntington's disease themselves (for example, a 2025 network-pharmacology analysis of valbenazine, deutetrabenazine, and vitamin E mechanisms, Tier D/computational, not drug-nutrient-depletion evidence). That research targets the underlying disease, not a deutetrabenazine depletion effect, and must not be read as supporting one.

Regulatory status

Not addressed in the deutetrabenazine label; no antioxidant-status monitoring requirement.

Population evidence

Two same-class (tetrabenazine, parent compound) studies, neither human, neither deutetrabenazine-specific. (1) MN9D mouse dopaminergic cell line, tetrabenazine 1 micromolar: no significant increase in reactive oxygen species; a significant decrease in NQO1 (NAD(P)H:quinone oxidoreductase 1, an Nrf2-pathway antioxidant-response enzyme), which the authors interpreted as evidence that VMAT2 inhibition does not trigger the same oxidative-stress response as direct mitochondrial inhibition, not as a marker of increased vulnerability (Adetuyi & Wimalasena, Toxics, 2025). (2) Caenorhabditis elegans polyglutamine Huntington's-disease model (strains AM134 Q0, EAK102 Q15, EAK103 Q128), tetrabenazine 100 micromolar: survival/lifespan significantly reduced versus control, rescued by vitamin C (0.5-1 millimolar) across genotypes (Gehan-Breslow-Wilcoxon and Mantel-Cox tests, n = 39-205 per group across three biological replicates); the authors hypothesized increased cytosolic-dopamine oxidative metabolism as the mechanism but did not directly measure reactive oxygen species, glutathione, or ascorbate levels (Tinoco-Bravo & Manjarrez, microPublication Biology, 2026).

Mechanism

VMAT2 inhibition raises cytosolic (non-vesicular) dopamine available for monoamine-oxidase-mediated or auto-oxidative metabolism, which can theoretically generate hydrogen peroxide and reactive quinones. This was measured directly (and found absent) in the negative cell study, and inferred indirectly (via antioxidant rescue of a survival phenotype, not a redox marker) in the positive animal-model study.

Counter-evidence held on record

Adjunct antioxidant research for tardive dyskinesia and Huntington's disease addresses oxidative stress intrinsic to those conditions, not a drug-induced depletion by deutetrabenazine. This entry's yellow grade reflects a contested, non-human, same-class mechanistic question only. No supplementation is suggested by this entry.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C mechanistic or class-level evidence, and no circulating consumer depletion claim naming this nutrient and this drug.

Channels tried

Broad web search in the original review (no drug-specific hits; only unrelated copper-deficiency case literature with no tetrabenazine/deutetrabenazine connection). A direct PubMed search-listing query for "tetrabenazine AND copper" was rate-limited (HTTP 429) in the original review but succeeded on a later repair pass, returning 3 results, reviewed by title: a case report on Wilson's disease (a copper-overaccumulation disorder) using tetrabenazine to treat the resulting chorea - a disease-intrinsic treatment context excluded under Hard Rule 2, not a drug-caused copper effect, and failing the cohort/mechanism test since the copper pathology in that report precedes and is independent of the tetrabenazine prescribed for it; an unrelated 1960s histamine/catatonia pharmacology study; and a radiochemistry paper on copper-64 isotope labeling of dihydrotetrabenazine for PET-imaging synthesis, which uses copper only as a radioisotope label with no bearing on physiological copper status. None of the three support a drug-caused copper finding in either direction.

Confidence

High that this is a genuine gap. Unlike the original review, the most targeted channel (a direct drug-specific PubMed query) worked cleanly on this repair pass rather than remaining blocked, and still returned nothing supporting a grade.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or Tier C evidence, and no circulating claim.

Channels tried

Broad web search in the original review (no drug-specific hits). A direct PubMed search-listing query for "tetrabenazine AND iron" was rate-limited (HTTP 429) in the original review, and remained blocked on a later repair pass across three further attempts: the same plain-phrasing PubMed retry, a broadened PubMed phrasing adding ferritin and "iron deficiency," and an Europe PMC REST API query, all returning HTTP 429. A Crossref API query for "tetrabenazine iron" did succeed on that repair pass and returned only administrative/reference-standard entries (USP monographs, pharmacology reference-book chapters), no article addressing iron status - a clean non-match from a channel that worked, which corroborates the gap even though the single most targeted channel (direct PubMed) is still blocked. Note on a tempting but inapplicable lead: a real dopamine-iron literature exists, but it concerns restless-legs-syndrome pathophysiology and dopamine-agonist therapy - the opposite pharmacology and a different drug class - and fails the cohort test for a VMAT2 inhibitor, so it supplies no Tier C support here.

Confidence

Moderate-to-high that this is a genuine gap, corroborated by the working Crossref channel, but the most targeted channel (direct PubMed) remains tooling-limited across two separate review passes now and should be re-tried again in a later revision.

Limits on what this shows

• Why no grade: Dual condition cleanly met: a direct PubMed search-listing query for "tetrabenazine AND (microbiome OR microbiota)" returned an explicit, clean zero-result page (the search engine confirmed it was processed without automatic term mapping because it retrieved zero results - not a block or timeout), and broad web search found no circulating consumer claim. This is the most confidently genuine gap in this dossier; the channel worked and the result was clean. A broadened repeat phrasing ("tetrabenazine AND 'gut microbiota'") attempted on a later repair pass was rate-limited (HTTP 429) and could not add further confirmation, but does not weaken the original clean zero-result finding, which stands unchanged.

Limits on what this shows

• Why no grade: A direct PubMed search-listing query for "tetrabenazine AND (hemoglobin OR anemia OR hematocrit OR oxygen)" worked cleanly and returned 13 results, all reviewed by title. None support a drug-caused nutrient-style finding: results were dominated by McLeod neuroacanthocytosis syndrome, a disease-intrinsic differential diagnosis for chorea with its own acanthocytosis/hemolysis biology unrelated to drug causation, and by a report describing tetrabenazine reducing cyanotic episodes of an unrelated paroxysmal disorder - a therapeutic effect of treating that disorder's own pathology, not a nutrient-pathway finding, and excluded here under the same rule that keeps a drug's own intended clinical benefit from being filed as a nutrient effect. No circulating consumer claim was found either. Dual condition met on a channel that worked, not one that was blocked. A broadened repeat PubMed query and a Crossref query ("tetrabenazine hemoglobin oxygen hematocrit") attempted on a later repair pass were both rate-limited (HTTP 429) and could not add further confirmation; the original 13-result review above stands unchanged.

Limits on what this shows

• Why no grade: The one same-class in vitro study identified that measured ATP directly (the 2025 MN9D dopaminergic-cell study used above for Mitochondrial burden and Oxidative stress) tested that endpoint only for rotenone and antimycin A; tetrabenazine was not included in the ATP assay in that study, only in the separate viability and reactive-oxygen-species assays. No other Tier B or Tier C source tying VMAT2 inhibition to ATP synthesis was located, and the 32-result PubMed search-listing query for "tetrabenazine AND (mitochondria OR mitochondrial)" was dominated by disease-intrinsic Huntington's-disease bioenergetics literature with no isolated deutetrabenazine/tetrabenazine ATP finding. No circulating consumer claim was found. Dual condition met; channels worked and were reviewed, not blocked. On a later repair pass, a broadened PubMed query ("deutetrabenazine AND (ATP OR oxidative phosphorylation OR energy metabolism)"), a Crossref query ("tetrabenazine mitochondrial ATP energy"), and a Semantic Scholar API query were all attempted and all rate-limited (HTTP 429); the original 32-result PubMed review above stands unchanged and is not weakened by those blocked retries.